Migraine Therapeutics Market Size to Grow by $ 1.06 bn through 2021-2025  

Technavio research projects the migraine therapeutics market to grow by $ 1.06 bn, accelerating at a CAGR of over 5% till 2025. The growth trajectory of the market is traced through a detailed analysis of the prevalent market forces, trends, and drivers along with competitive benchmarking

Migraine Therapeutics Market: Receive FREE Sample Report

Migraine Therapeutics Market: Key Market Driver

One of the primary factors that will trigger the growth of the migraine therapeutics market size is increase in the number of patients suffering from migraine. This research report provides a comprehensive analysis of all the factors that are likely to propel market growth, taking into account the market trends as well as challenges that are likely to impede growth. The objective of this research report is to equip clients with actionable insights that will help them leverage opportunities and formulate growth strategies for their business.

Migraine Therapeutics Market: Vendor Analysis

The market is fragmented due to the presence of several players. The growth of the players depends on several factors such as market conditions, government support, and industry development. To survive and succeed in such an intensely competitive market, players must distinguish their product and service offerings through clear and unique value propositions. AbbVie Inc., Amgen Inc., Eli Lilly and Co., eNeura Inc., GlaxoSmithKline Plc, Grunenthal GmbH, H. Lundbeck AS, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Upsher-Smith Laboratories LLC are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their position in the slow-growing segments.

Technavio also offers custom research reports with detailed insights assessing the market from a global as well as regional perspective. This customized report will help clients keep up with new product launches in direct & indirect or related markets. It will also provide insights on upcoming developments along with a pipeline analysis of vendor operations and the impact of government regulations.

For more insights on this market: Download a Free Sample Report

Technavio has been monitoring the Global Migraine Therapeutics Market and is expected to grow by $ 1.06 billion, progressing at a CAGR of over 5% during the forecast period. The growth trajectory of the market is traced through a detailed analysis of the prevalent market forces, trends, and drivers along with competitive benchmarking. View Free Sample Report

Migraine Therapeutics Market: Advances in migraine research to drive growth

North America accounted for the largest growth share with 38% of the market growth set to originate from North America during the forecast period. The US is one of the key markets for migraine therapeutics in North America. Market growth in this region will be slower than the growth of the market in Europe and Asia. The rising healthcare expenditure will facilitate the migraine therapeutics market growth in North America over the forecast period. Advances in migraine research have led to the emergence of novel preventive migraine treatment methods.

The increasing number of patients suffering from migraine is one of major factors driving the migraine therapeutics market growth.  Migraine is a highly prevalent neurological disease that exists primarily in the Americas, followed by Europe and some regions of Africa and Asia. Frequent consumption of medications can lead to the development of a disabling condition termed medication-overuse headache (MOH).  Women are highly susceptible to migraine and have limited response to migraine treatment, due to the fluctuations in the female reproductive hormones, estrogen. Fluctuating hormone levels cause migraine and limit the effectiveness of the various migraine therapeutics on women.  The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. 

Migraine Therapeutics Market: Vendor Analysis

The market is fragmented. The growth of the players depends on several factors such as market conditions, government support, and industry development. To survive and succeed in such an intensely competitive market, players must distinguish their product and service offerings through clear and unique value propositions. AbbVie Inc., Amgen Inc., Eli Lilly and Co., eNeura Inc., GlaxoSmithKline Plc, Grunenthal GmbH, H. Lundbeck AS, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Upsher-Smith Laboratories LLCare some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their position in the slow-growing segments.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19 Download a Free Sample Report 

Migraine Therapeutics Market: Key Highlights of the Report for 2021-2025

• CAGR of the market during the forecast period 2021-2025
• Detailed information on factors that will drive Migraine Therapeutics Market growth during the next five years
• Precise estimation of the Migraine Therapeutics Market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the migraine therapeutics industry across APAC, Europe, MEA, North America, and South America
• A thorough analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of Migraine Therapeutics Market vendors